TNFRSF8 and systemic sclerosis: A Phase IIb clinical trial (NCT03222492) showed that BV treatment in patients with severe, active diffuse cutaneous SSc achieved the primary endpoint (a decrease of ≥ 8 in the modified Rodnan skin score) within 24 weeks, demonstrating the efficacy of CD30-targeting strategies in treating fibrotic diseases and suggesting the promise of BV in SSc treatment[86,87].